$BRVE

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E

Analysts made several calls on Monday. Morgan Stanley initiated Attovia Therapeutics with an overweight rating and $39 target. UBS upgraded Kaiser Aluminum to buy with an $184 target. Baird upgraded Deere to outperform. Jefferies reiterated Apple as underperform, citing potential downside risks. Bernstein reiterated SpaceX as outperform but noted uncertainty in its direct-to-device mobile business. Melius reiterated Nvidia as buy, suggesting potential upside. Goldman Sachs initiated Braveheart B

Analysts initiated coverage on five companies: Evercore ISI rated Lumentum (LITE) Outperform with $1,100 target; BTIG rated Smith & Nephew (SNN) Neutral; Morgan Stanley rated Attovia (ATTO) Overweight with $39 target; Roth Capital rated Ticketplus (TP) Buy with $14 target; Stifel rated Braveheart Bio (BRVE) Buy with $45 target.

Cantor Fitzgerald initiated coverage on Braveheart Bio (NASDAQ:BRVE) with an overweight rating and a $40 price target. The company, valued at $1.76 billion, is unprofitable with a -$2.63 EPS. Its focus is on BHB-1893, a cardiac myosin inhibitor. Other analysts have also rated BRVE favorably, with price targets up to $48. The stock surged post-IPO, raising $382.5 million.

Jefferies initiated coverage of Braveheart Bio with a Buy rating and $48 price target, implying 75% upside. The biotech raised $382.5M in its IPO, developing BHB-1893 for hypertrophic cardiomyopathy. Jefferies analysts cited superior Phase II data compared to competitors' treatments. Global Phase III trials are expected to begin in 2026-2027, with potential accelerated FDA filing by year-end 2027.

OrbiMed Advisors disclosed a 17.2% stake in Braveheart Bio, totaling 12.18 million shares, via a Schedule 13D filing. The investment was made for potential gains, not control, and may be adjusted based on future assessments. OrbiMed focuses on healthcare and life sciences investments.

AH Bio Fund IV, L.P. purchased 1,100,000 indirectly-held shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($19.80M total) on 2026-08-07.

Chimovits Erez purchased 1,940,000 indirectly-held shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($34.92M total) across 2 trades on 2026-08-07.

ORBIMED ADVISORS LLC purchased 1,940,000 indirectly-held shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($34.92M total) across 2 trades on 2026-08-07.

Braveheart Bio (BRVE) said director Christopher Viehbacher bought 83,333 shares at $18.00 each on Aug. 7, 2026, via exercise of stock options, per an SEC Form 4. The purchase raised his direct stake by about 12% to 609,519 shares. Braveheart is a clinical-stage biotech developing BHB-1839 for hypertrophic cardiomyopathy.